---
title: "\"Performance\" Abbott's revenue last quarter fell short of expectations, adjusting the full-year profit forecast"
description: "Abbott Laboratories announced that total revenue for the third quarter was $11.37 billion, slightly below the market expectation of $11.4 billion, as weakness in its diagnostics and nutrition business"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261293934.md"
published_at: "2025-10-15T14:26:57.000Z"
---

# "Performance" Abbott's revenue last quarter fell short of expectations, adjusting the full-year profit forecast

> Abbott Laboratories announced that total revenue for the third quarter was $11.37 billion, slightly below the market expectation of $11.4 billion, as weakness in its diagnostics and nutrition businesses offset strong demand for its medical devices; adjusted earnings per share were $1.30, in line with expectations. The company stated that it currently expects annual adjusted earnings per share to be between $5.12 and $5.18, compared to the previous expectation of $5.10 to $5.20

Abbott Laboratories (ABT.US) announced that total revenue for the third quarter was $11.37 billion, slightly below the market expectation of $11.4 billion, as weakness in its diagnostics and nutrition businesses offset strong demand for its medical devices; adjusted earnings per share were $1.30, in line with expectations.

The company stated that it currently expects annual adjusted earnings per share to be between $5.12 and $5.18, compared to the previous expectation of $5.10 to $5.20

### Related Stocks

- [ABT.US - Abbott Laboratories](https://longbridge.com/en/quote/ABT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 雅培印度公司在 12 月季度的利潤為 37.6 億盧比 | 雅培印度有限公司：雅培印度 12 月季度利潤為 37.6 億印度盧比；雅培印度 12 月季度營業收入為 172.4 億印度盧比 | [Link](https://longbridge.com/en/news/275719891.md) |
| 關鍵事實：精密科學計劃在 2026 年第二季度與雅培合併；預計 2025 年收入增長 18% | 精密科學公司正在與雅培合併，預計將在 2026 年第二季度完成，待批准。該公司還結束了與 Freenome Holdings 交易的等待期。精密科學公司在 2025 年的收入增長了 18%，達到 32.5 億美元。篩查收入增長了 26%，達 | [Link](https://longbridge.com/en/news/275986686.md) |
| 雅培｜8-K：2025 財年 Q4 營收 115 億美元不及預期 |  | [Link](https://longbridge.com/en/news/273373303.md) |
| 市場對雅培的態度是看漲還是看跌？ | 雅培（Abbott Laboratories，NYSE:ABT）的空頭頭寸減少了 14.02%，目前有 1588 萬股被賣空，佔可交易股份的 0.92%。交易者需要平均 2.82 天來平倉他們的空頭頭寸。空頭頭寸的下降表明市場對雅培的看漲情 | [Link](https://longbridge.com/en/news/272305312.md) |
| 雅培公司財報發佈前你需要了解的關鍵信息 | 在雅培財報發佈前你需要知道的事項 | [Link](https://longbridge.com/en/news/270846657.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.